Multiple Myeloma Clinical Trial
Official title:
Phase III Trial Comparing Treatment With Melphalan+Prednisolon (MP) With Melphalan+Prednisolon+Thalidomide (MPT) for Previously Untreated Elderly Patients With Multiple Myeloma
Verified date | August 2013 |
Source | Erkim Ilac A.S. |
Contact | n/a |
Is FDA regulated | No |
Health authority | Turkey: Ministry of Health |
Study type | Interventional |
This is a multi-centre Phase III randomized controlled study of patients with multiple
myeloma (MM). Eligible patients who are not candidates for transplantation will be
randomized to receive eight courses of Melphalan/Prednisolone with or without Thalidomide
treatment. Thalidomide will be initiated at the dose of 100 mg/day and maintained at 100
mg/day. The patients will be assessed for any responses at the end of 2nd, 4th, 6th and 8th
cycles of treatment. The toxicities will be assessed at monthly intervals. Patients will be
assessed for the:
1. Incidence and grade of any toxicity
2. Level of maximum disease response
3. Time to disease progression
4. Time to death
Status | Completed |
Enrollment | 122 |
Est. completion date | September 2012 |
Est. primary completion date | September 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 55 Years and older |
Eligibility |
Inclusion Criteria: - Age above 55 years old. - Diagnosis of MM (Appendix A) and staging (Appendix B), previously untreated. - Performance status ECOG, 0, 1, or 2 (Appendix C). - Written informed consent to the study medications and bone marrow biopsy at diagnosis, 12 weeks and 6 months and/or off-study assessment. - Women who are pregnant or lactating at the time of diagnosis are ineligible. All women of child-bearing potential must have a negative pregnancy test within 24hrs of commencing the thalidomide and must take adequate precautions to prevent pregnancy and should not plan on conceiving children during the treatment program: - Adequate precautions are defined as "at least one highly effective method i.e., IUD, hormonal (birth control pills, injections, or implants), tubal ligation, partner's vasectomy AND one additional effective method i.e., latex condom, diaphragm, cervical cap". - Women becoming pregnant on protocol will be removed immediately from protocol. - Male patients (including patients having had a vasectomy) must use barrier contraception during and for four weeks after completing the thalidomide. - Patients remain eligible in the presence of abnormal renal function and/or liver function at time of enrollment. - Absence of severe dementia, able to take medication at home. - Absence of systemic disorders (gastrointestinal, pulmonary, cardiac and neurological). Exclusion Criteria: - Asymptomatic myeloma or solitary plasmacytoma of bone or extramedullary plasmacytoma (without evidence of myeloma). - Previous or concurrent active malignancies, except surgically removed basal cell carcinoma of the skin or other in situ carcinomas. - Previous treatment for myeloma, except minimal local radiotherapy to relieve bone pain. - Other illnesses which would preclude chemotherapy administration or patient compliance. - Any other serious medical or psychiatric illness which would prevent informed consent. - Peripheral neuropathy > NCI criteria grade 2. - Pregnant or lactating women and patients of childbearing age who refuse to use contraception. - History of hypersensitivity to thalidomide or any component of the medications. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Turkey | Baskent University School of Medicine Education and Research Hospital, Hematology Department | Adana | |
Turkey | Ankara Numune Education and Research Hospital,Hematology Department | Ankara | |
Turkey | Ankara University School of Medicine, Hematology Department | Ankara | |
Turkey | Gazi University School of Medicine, Hematology Department | Ankara | |
Turkey | Hacettepe University School of Medicine, Hematology Department | Ankara | |
Turkey | Akdeniz University School of Medicine , Hematology Department | Antalya | |
Turkey | Uludag University School of Medicine, Hematology Department | Bursa | |
Turkey | Osmangazi University School of Medicine , Hematology Department | Eskisehir | |
Turkey | Marmara University School of Medicine, Hematology Department | Istanbul |
Lead Sponsor | Collaborator |
---|---|
Cigdem Sahinbas YILMAZ | Turkish Society of Hematology Myeloma Study Group |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | response rate | 12 months | No | |
Secondary | time to relapse | 18 months | No | |
Secondary | overall survival | unlimited | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |